Tech Company Financing Transactions
Kyras Therapeutics Funding Round
Versant Ventures and private investors invested in a Series A funding round for Kyras Therapeutics. This venture round was announced on 12/14/2015.
Transaction Overview
Company Name
Announced On
12/14/2015
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Versant Ventures (Lead Investor) (Brad Bolzon)
private investors (Carlo Rizzuto)
private investors (Joe Vacca)
Proceeds Purpose
The company will use the funds to develop the RAS family of proteins.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
430 East 29th St. 1005
New York, NY 10016
USA
New York, NY 10016
USA
Phone
Undisclosed
Website
Email Address
Overview
Kyras is a biopharmaceutical company developing drugs that address currently incurable cancers and developmental disorders caused by RAS gene mutations. We are a team of experienced scientists, drug developers, and entrepreneurs dedicated to advancing novel medicines to improve patients' lives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carlo Rizzuto
Chief Scientific Officer
Joe Vacca
Browse more venture capital transactions:
Prev: 12/14/2015: Sightly venture capital transaction
Next: 12/14/2015: Iron Gaming venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs